GET DAILY SIGNALSGlaukos (GKOS) Rises +48% Over the Past 30 Days After Strong Q3 Results
Key Takeaways
- Glaukos (GKOS) shares climbed roughly 48% over the past 30 days, rising from about $158.55 on September 29, 2026, to approximately $234.92 intraday on October 29, 2026.
- The move was driven primarily by a blowout third-quarter 2026 report, with record net sales of $211 million, up 58% year over year and well above consensus estimates.
- Management raised full-year 2026 net sales guidance to $775–$785 million and introduced a preliminary 2027 revenue target of about $1 billion.
- Growth was powered by the company's two transformational commercial drivers: iDose TR (roughly $76 million in Q3 sales) and Epioxa (about $53 million).
- Several Wall Street analysts raised price targets following the report, reflecting a significant re-rating of the company's growth profile.
- Over the last quarter, GKOS has gained roughly 45%, recovering from a September pullback and moving beyond prior all-time highs.
- For additional detail, explore GKOS's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to discover AI-driven trading strategies.
Glaukos (GKOS) Company Overview and Market Position
Glaukos Corporation (GKOS) is an ophthalmic pharmaceutical and medical technology company headquartered in Aliso Viejo, California, focused on novel therapies for glaucoma, corneal disorders, and retinal diseases. Its portfolio spans five "dropless" technology platforms: iStent micro-scale surgical devices used in micro-invasive glaucoma surgery (MIGS); iDose sustained-release procedural pharmaceuticals, including the continuous-release glaucoma implant iDose TR; iLink bio-activated pharmaceuticals, including Epioxa, the first FDA-approved epithelium-on corneal cross-linking therapy for keratoconus; iLution transdermal pharmaceuticals; and Retina XR bio-erodible sustained-release therapies. Investors follow GKOS for its evolution from a glaucoma-focused device maker into a diversified ophthalmology growth platform with multiple expanding addressable markets. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Glaukos (GKOS) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, GKOS has risen approximately 48%, moving from a closing price of $158.55 on September 29, 2026, to roughly $234.92 intraday on October 29, 2026. A substantial portion of that gain occurred in a single session following third-quarter results, when shares surged more than 25% in pre-market and early trading.
The last quarter tells a similar but more volatile story. From a closing level near $161.66 on July 29, 2026, the stock has climbed roughly 45%. That advance was not linear: shares reached an all-time intraday high around $191.62 in late August before pulling back into the $153–$158 range in late September. The stock then recovered through October and re-rated sharply higher after the Q3 earnings report, reflecting renewed conviction in the company's growth trajectory. From what I see, the recovery highlights how quickly sentiment can shift on solid execution.
What Drove GKOS Stock Price in the Last 30 Days
The dominant catalyst was Glaukos's third-quarter 2026 results, reported on October 28. The company posted record net sales of $211 million, up 58% year over year and roughly 25% above consensus estimates, while non-GAAP earnings per share of $0.47 compared with an expected loss. Management raised full-year 2026 guidance to $775–$785 million from a prior range of $680–$700 million and introduced a preliminary 2027 revenue target of approximately $1 billion.
The quarter showed accelerating commercial traction across key franchises. Corneal Health revenue rose 154% year over year to $59 million, led by approximately $53 million in Epioxa sales, while U.S. Glaucoma revenue increased 47% to $118.6 million, supported by roughly $76 million from iDose TR. Non-GAAP gross margin expanded roughly 400 basis points to about 88%. Following the report, analysts at firms including Piper Sandler, Needham, BTIG, Stifel, Mizuho, and Truist raised their price targets, reinforcing the upward move.
Additional developments contributed to sentiment earlier in the month, including positive Phase 4 topline results for iDose TR in combination with cataract surgery announced on October 9, an exclusive licensing agreement with RevOpsis Therapeutics for the investigational retinal biologic RO-104 announced October 8, and positive three-year extension data for Epioxa.
What Drove GKOS Stock Performance Over the Last Quarter
The broader quarterly advance reflects a multi-month fundamental acceleration. Second-quarter results reported July 29 showed net sales up about 50% year over year to a record $185.6 million, prompting an earlier guidance increase. The Epioxa launch progressed through the quarter, supported by the July 1 effective date of its product-specific J-code, J2789, while iDose TR continued to expand surgeon adoption and utilization. These drivers were partly offset in September by profit-taking and uncertainty around proposed Medicare local coverage determinations (LCDs) for iDose TR, which contributed to the interim pullback before the October re-rating. I’m watching this closely as reimbursement clarity could influence the next leg higher.
GKOS Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape GKOS's trajectory in the coming quarters. The pace of Epioxa commercialization remains central, including continued expansion of its site-of-care network and payer access. Medicare local coverage determinations for iDose TR represent a key reimbursement risk to monitor. Management's preliminary 2027 revenue target of roughly $1 billion will be refined over time, and investors will watch for clarity on franchise-level contributions. The pipeline also carries catalysts, including iDose TREX and iDose TRIO, the PRESERFLO MicroShunt program, and early retinal biologic development. Management has indicated operating expenses are expected to grow 25–30% in the fourth quarter, which could pressure near-term margins even as revenue scales. These factors, alongside broader healthcare policy and macroeconomic conditions, will inform how the market assesses the stock's elevated valuation.
Exploring Tickeron AI Tools in Practice
In my own research, I frequently use Tickeron’s AI Trading Bots to evaluate how automated strategies might align with fundamental shifts like those seen at GKOS. These tools let me compare different approaches across timeframes and market conditions, providing another layer of perspective alongside earnings data and analyst updates. It has become a practical part of how I cross-check ideas before forming a fuller view.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for GKOS turns positive, indicating new upward trend
GKOS saw its Momentum Indicator move above the 0 level on October 05, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned positive. In 78 of the 92 cases, the stock moved higher in the following days. The odds of a move higher are at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for GKOS just turned positive on October 02, 2026. Looking at past instances where GKOS's MACD turned positive, the stock continued to rise in 43 of 58 cases over the following month. The odds of a continued upward trend are 74%.
GKOS moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GKOS crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Following a +33.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where GKOS advanced for three days, in 248 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GKOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
GKOS broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GKOS entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 16 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. GKOS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.535) is normal, around the industry mean (4.201). P/E Ratio (-72.661) is within average values for comparable stocks, (1.335). Projected Growth (PEG Ratio) (12.570) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (15.456) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an ophthalmic medical device company
Industry MedicalNursingServices